Intravascular NK/T cell lymphoma: report of 2 cases and review of literature
10.3760/cma.j.cn115356-20220830-00247
- VernacularTitle:血管内NK/T细胞淋巴瘤2例并文献复习
- Author:
Longrong RAN
1
;
Pengzhen WANG
;
Zailin YANG
Author Information
1. 重庆大学附属肿瘤医院血液肿瘤中心 肿瘤转移与个体化诊治转化研究重庆市重点实验室，重庆 400030
- Keywords:
Intravascular NK/T-cell lymphoma;
Diagnosis;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2023;32(10):605-608
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features,differential diagnosis and treatment of intravascular NK/T cell lymphoma.Methods:The clinical data and diagnosis and treatment process of 2 patients with intravascular NK/T cell lymphoma admitted to Chongqing University Cancer Hospital were retrospectively analyzed, and related literatures were reviewed.Results:Both patients were initially presented with cutaneous symptoms. Patient 1 was diagnosed with intravascular NK/T cell lymphoma, and received 4 courses of programmed-death receptor 1 (PD-1) inhibitor toripalimab + P-Gemox (pegaspargase + gemcitabine + oxaliplatin) regimen, 1 course of PD-1 + ME (toripalimab + mitoxantrone + etoposide) regimen and then underwent autologous hematopoietic stem cell transplantation; patient 2 was diagnosed with intravascular NK/T cell lymphoma involving the nasal cavity, and received 4 courses of P-Gemox regimen, and then received autologous hematopoietic stem cell transplantation in the other hospital. Both patients achieved good therapeutic efficacy.Conclusions:Intravascular NK/T cell lymphoma is very rare, frequently involving the skin and central nervous system. Intravascular growth of tumor cells derived from NK cells is the key point of diagnosis and differential diagnosis. P-Gemox regimen and hematopoietic stem cell transplantation could bring better curative effect.
